A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance data...

Date 24 November 2018
Event ESMO Asia 2018 Congress
Session Poster display - Cocktail
Topics Gastric Cancer
Bioethics, Legal, and Economic Issues
Presenter Keun-Wook Lee
Citation Annals of Oncology (2018) 29 (suppl_9): ix46-ix66. 10.1093/annonc/mdy432
Authors K. Lee1, I.S. Choi2, J.H. Kim3
  • 1Internal Medicine, Seoul National University College of Medine / Seoul National University Bundang Hospital, 463-707 - Seongnam/KR
  • 2Internal Medicine, Seoul Metropolitan Government Seoul National University Boramae Medical Center, 07061 - Seoul/KR
  • 3Department Of Internal Medicine, Seoul National University Bundang Hospital, Seoul National University College of Medicine, 463-707 - Seongnam/KR

Abstract

Background

The survival benefit of second-line chemotherapy in patients with metastatic gastric cancer (MGC) has recently been established. We conducted a nationwide population-based outcomes study of patients with MGC receiving second-line chemotherapy to better understand real-world treatment patterns and outcomes.

Methods

Data were collected from the Health Insurance Review and Assessment Service database. We identified 509 newly diagnosed patients with MGC in 2010 who received second-line chemotherapy. These patients were divided into three groups for analyses: Group A comprised all patients who received second-line chemotherapy (N = 509); Group B comprised those who received fluoropyrimidine (Fp) plus platinum as first-line treatment, followed by irinotecan-based or taxane-based regimens as second-line chemotherapy (N = 284); and Group C comprised those who received Fp plus cisplatin as first-line treatment, followed by 5-fluorouracil (5-FU)/oxaliplatin, irinotecan-based, or taxane-based regimens as second-line chemotherapy (N = 184).

Results

Among patients who received first-line chemotherapy, 47.2% (509/1,078) continued to receive second-line chemotherapy. The most commonly used second-line chemotherapy regimens were 5-FU/irinotecan, 5-FU/oxaliplatin, and docetaxel. The median overall survival (OS) of all 509 patients was 5.2 months. The time from the start date of first-line chemotherapy to the start date of second-line chemotherapy > 6.1 months was an independent prognostic factor for improved OS. The type of chemotherapy regimen was not a significant factor affecting OS.

Conclusions

The findings provide a better understanding of second-line treatment patterns and outcomes in patients with MGC and will help guide treatment decisions in real-world clinical practice.

Editorial acknowledgement

Clinical trial identification

Legal entity responsible for the study

Keun-Wook Lee.

Funding

Has not received any funding.

Disclosure

All authors have declared no conflicts of interest.